Steroidal Anti-Leishmanial Drug
Tech ID
P27-1382
Patent Status
Published in India
Design Status
--
Technical Description
This technology is a novel steroidal alkaloid-based drug, veratramine, designed to inhibit LdDPCK enzyme in Leishmania donovani for therapeutic application.
Problems Addressed
- Limited Drug Efficacy
- Limited Treatment Accessibility
- Severe Side Effects
- Unresponsive Parasite Strains
- Reduced Immunotherapy Success
- Limited Leishmanicidal Activity
- High Treatment Costs
TARGET AUDIENCE
- Pharmaceutical Industry
- Biotechnology Sector
- Healthcare Industry
- Academic & Research Institutions
- Therapeutics & Prevention Sector
TECH FEATURES
- Efficient Steroidal Composition
- Enhanced Anti-Leishmanial Activity
- Targeted Kinase Inhibition
- Potent Drug Molecule
- Optimized Parasite Management
- Advanced Resistance Control
P27-1382
Send download link to email.
Available For
Available for exclusive and non exclusive license
Sell off
Cost
—
Stage of Developments
Technology Validated
Contact Person
Mr. Lalit Ambastha
IP Bazzaar Technology Pvt. Ltd.
IP Bazzaar Technology Pvt. Ltd.
12 First Floor, National Park, Lajpat Nagar-IV,
New Delhi-110024, India
Tel: [+91] 11-26360036;
Fax: [+91] 11-26360037;
Mobile: [+91]9811367838;
Email: tech@ipbazzaar.com;
www.ipbazzaar.com
New Delhi-110024, India
Tel: [+91] 11-26360036;
Fax: [+91] 11-26360037;
Mobile: [+91]9811367838;
Email: tech@ipbazzaar.com;
www.ipbazzaar.com